

## **Retired Policy**

## Circulating Tumor DNA Management of Non-Small Cell Lung Cancer (Liquid Biopsy)

**Policy** # 00597


Original Effective Date: 03/21/2018

Retired Date: 04/11/2022

Note: This medical policy has been merged with medical policy 00452 Molecular Analysis (Including Liquid Biopsy) for Targeted Therapy or Immunotherapy of Non-Small-Cell Lung Cancer.

Circulating Tumor DNA Management of Non-Small Cell Lung Cancer (Liquid Biopsy) was retired effective 04/11/2022.

A retired medical policy is no longer active and is not utilized for coverage eligibility determination or claims processing as of the retired date.



Blue Cross and Blue Shield of Louisiana is an independent licensee of the Blue Cross and Blue Shield Association and incorporated as Louisiana Health Service & Indemnity Company.

No part of this publication may be reproduced, stored in a retrieval system, or transmitted, in any form or by any means, electronic, mechanical, photocopying, or otherwise, without permission from Blue Cross and Blue Shield of Louisiana.